ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO445

Arterial Stiffness and Kidney Function Decline in SPRINT

Session Information

Category: Hypertension and CVD

  • 1401 Hypertension and CVD: Epidemiology, Risk Factors, and Prevention

Authors

  • Nowak, Kristen L., University of Colorado Denver: Anschutz Medical Campus, Aurora, Colorado, United States
  • Jovanovich, Anna Jeanette, University of Colorado Denver: Anschutz Medical Campus, Aurora, Colorado, United States
  • You, Zhiying, University of Colorado Denver: Anschutz Medical Campus, Aurora, Colorado, United States
  • Chonchol, Michel, University of Colorado Denver: Anschutz Medical Campus, Aurora, Colorado, United States
  • Supiano, Mark A., University of Utah and VA Salt Lake City, Salt Lake City, Utah, United States
Background

Arterial stiffness increases with advancing age and chronic kidney disease. Arterial stiffness may contribute to a decline in kidney function; however, evidence is inconsistent. We hypothesized that greater baseline arterial stiffness was independently associated with rapid decline in kidney function over the longitudinal follow-up period in the Systolic Blood Pressure Intervention Trial (SPRINT).

Methods

538 adults who participated in an ancillary study of SPRINT which measured arterial stiffness (aortic pulse-wave velocity [aPWV]) were included in this analysis. Multivariable logistic regression was used to examine the association between baseline aPWV and rapid decline in kidney function (estimated glomerular filtration [eGFR] decline >3 ml/min/1.73m2/yr) over the follow-up period (median of 3.7 yrs).

Results

Mean age was 72+3 years with a mean baseline aPWV of 10.6+2.6 m/sec and eGFR of 67+21 ml/min/1.73 m2. 109 participants had rapid decline in renal function over the follow-up period. After adjustment demographics, randomization group, co-morbid conditions, smoking, body-mass index, estimated glomerular filtration rate, urinary albumin to creatinine ratio, antihypertensive medications, systolic blood pressure, and heart rate, baseline aPWV was not associated with increased odds of rapid decline in kidney function (OR: 1.03, 95% CI: 0.93-1.13 per unit increase in aPWV). In the fully adjusted model, baseline aPWV above the median also did not associate with rapid decline in kidney function (OR: 0.92, 95% CI: 0.56-1.51).

Conclusion

Among adults at high risk for cardiovascular events, greater arterial stiffness is not associated with rapid decline in kidney function.

Funding

  • NIDDK Support